Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation

SA Kemp, DA Collier, R Datir, IATM Ferreira, S Gayed, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova, Ines Ushiro Lumb, David J Roberts, Anita Chandra, N Temperton, The CITIID-NIHR BioResource COVID-19 Collaboration, The COVID-19 Genomics UK (COG-UK) Consortium, K Sharrocks, E Blane, JAG Briggs, MJ van Gils, KGC Smith, JR Bradley, C Smith, R Doffinger, L Ceron-Gutierrez, G Barcenas-Morales, DD Pollock, RA Goldstein, A Smielewska, JP Skittrall, T Gouliouris, IG Goodfellow, E Gkrania-Klotsas, CJR Illingworth, LE McCoy, View ORCID ProfileRK Gupta
doi: https://doi.org/10.1101/2020.12.05.20241927
SA Kemp
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DA Collier
1Division of Infection and Immunity, University College London, London, UK
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Datir
1Division of Infection and Immunity, University College London, London, UK
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IATM Ferreira
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Gayed
4Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Jahun
5Department of Pathology, University of Cambridge, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Hosmillo
5Department of Pathology, University of Cambridge, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Rees-Spear
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Mlcochova
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ines Ushiro Lumb
6NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J Roberts
6NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Chandra
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Temperton
7Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Sharrocks
4Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Blane
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAG Briggs
10Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MJ van Gils
11Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KGC Smith
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JR Bradley
3Department of Medicine, University of Cambridge, Cambridge, UK
12NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Smith
13Department of Virology, Cambridge University NHS Hospitals Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Doffinger
15Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Ceron-Gutierrez
15Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Barcenas-Morales
15Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DD Pollock
16Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RA Goldstein
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Smielewska
5Department of Pathology, University of Cambridge, Cambridge
13Department of Virology, Cambridge University NHS Hospitals Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JP Skittrall
4Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
14Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
17Clinical Microbiology and Public Health Laboratory, Addenbrookes’ Hospital, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T Gouliouris
4Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IG Goodfellow
5Department of Pathology, University of Cambridge, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Gkrania-Klotsas
4Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CJR Illingworth
14Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK
18MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LE McCoy
1Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RK Gupta
2Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
3Department of Medicine, University of Cambridge, Cambridge, UK
19Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for RK Gupta
  • For correspondence: rkg20@cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and ΔH69/ΔV70 in the S1 N-terminal domain NTD of the Spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype diminished in frequency, before returning during a final, unsuccessful course of convalescent plasma. In vitro, the Spike escape double mutant bearing ΔH69/ΔV70 and D796H conferred decreased sensitivity to convalescent plasma, whilst maintaining infectivity similar to wild type. D796H appeared to be the main contributor to decreased susceptibility, but incurred an infectivity defect. The ΔH69/ΔV70 single mutant had two-fold higher infectivity compared to wild type and appeared to compensate for the reduced infectivity of D796H. Consistent with the observed mutations being outside the RBD, monoclonal antibodies targeting the RBD were not impacted by either or both mutations, but a non RBD binding monoclonal antibody was less potent against ΔH69/ΔV70 and the double mutant. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy associated with emergence of viral variants with reduced susceptibility to neutralising antibodies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: MC_UU_00002/11). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous donations from UCLs supporters alumni and friends (LEM). JAGB is supported by the Medical Research Council (MC_UP_1201/16).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the East of England Cambridge Central Research Ethics Committee (17/EE/0025). The patient provided written informed consent. Additional controls with COVID19 were enrolled to the NIHR BioResource Centre Cambridge under ethics review board (17/EE/0025). Written consent to publish the report was obtained after death from the patients family.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵8 The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix for author list

  • ↵9 The COVID-19 Genomics UK (COG-UK) Consortium, https://www.cogconsortium.uk. Full list of consortium names and affiliations are in the appendix

  • We have updated the deep sequence analysis showing that N501Y transiently emerges We have also shown there that the del69/70 increases infectivity of Spike by two fold We show reduced susceptibility to convalescent plasma is due to D796H

Data Availability

Long-read sequencing data that support the findings of this study have been deposited in the NCBI SRA database with the accession codes SAMN16976824 - SAMN16976846 under BioProject PRJNA682013 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA682013). Short reads and data used to construct figures were deposited at https://github.com/Steven-Kemp/sequence_files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 29, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
SA Kemp, DA Collier, R Datir, IATM Ferreira, S Gayed, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova, Ines Ushiro Lumb, David J Roberts, Anita Chandra, N Temperton, The CITIID-NIHR BioResource COVID-19 Collaboration, The COVID-19 Genomics UK (COG-UK) Consortium, K Sharrocks, E Blane, JAG Briggs, MJ van Gils, KGC Smith, JR Bradley, C Smith, R Doffinger, L Ceron-Gutierrez, G Barcenas-Morales, DD Pollock, RA Goldstein, A Smielewska, JP Skittrall, T Gouliouris, IG Goodfellow, E Gkrania-Klotsas, CJR Illingworth, LE McCoy, RK Gupta
medRxiv 2020.12.05.20241927; doi: https://doi.org/10.1101/2020.12.05.20241927
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
SA Kemp, DA Collier, R Datir, IATM Ferreira, S Gayed, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova, Ines Ushiro Lumb, David J Roberts, Anita Chandra, N Temperton, The CITIID-NIHR BioResource COVID-19 Collaboration, The COVID-19 Genomics UK (COG-UK) Consortium, K Sharrocks, E Blane, JAG Briggs, MJ van Gils, KGC Smith, JR Bradley, C Smith, R Doffinger, L Ceron-Gutierrez, G Barcenas-Morales, DD Pollock, RA Goldstein, A Smielewska, JP Skittrall, T Gouliouris, IG Goodfellow, E Gkrania-Klotsas, CJR Illingworth, LE McCoy, RK Gupta
medRxiv 2020.12.05.20241927; doi: https://doi.org/10.1101/2020.12.05.20241927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2467)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)